Chulhun L. Chang

Prof. Dr. Chulhun L. Chang

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2015 in Proteomics
Verified
Journal Article
Closed access
PDF file
JLJaewook Lee
Jaewook Lee
DCDongsic Choi
Dongsic Choi
JLJong Seok Lee
Jong Seok Lee
DKDae‐Kyum Kim
Dae‐Kyum Kim
GGGyeongyun Go
Gyeongyun Go
YGYong Song Gho
Yong Song Gho

1 February 2009 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
MPMi Young Park
Mi Young Park
YKYoung Jin Kim
Young Jin Kim
SHSANG-HYUN HWANG
SANG-HYUN HWANG
HKHyoung Hoi Kim
Hyoung Hoi Kim
ELEun Yup Lee
Eun Yup Lee
CCChulhun L. Chang
Chulhun L. Chang
We evaluated a new immunochromatographic assay (ICA) using mouse monoclonal anti-MPT64 antibody for rapid discrimination between Mycobacterium tuberculosis and nontuberculous mycobacteria in clinical isolates. A study with mycobacteria and other organisms showed excellent sensitivity (≅99%) and specificity (100%) and an appropriate detection limit (10 5 CFU/ml) when tested with M. tuberculosis H37Rv. This ICA can simplify the identification of M. tuberculosis in clinical laboratories.

1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
PEPhyu Win Ei
Phyu Win Ei
WAWAH WAH AUNG
WAH WAH AUNG
JLJongseok LEE
Jongseok LEE
GCGo-Eun Choi
Go-Eun Choi
CCChulhun L. Chang
Chulhun L. Chang
Ei PW, et al. J Korean Med Sci. 2016 Nov;31(11):1673-1683. https://doi.org/10.3346/jkms.2016.31.11.1673

1 November 2019 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
DPDong Chul Park
Dong Chul Park
Si Hyun KimSi Hyun Kim
Si Hyun Kim
DYDongeun Yong
Dongeun Yong
ISIn Bum Suh
In Bum Suh
YKYoung Ah Kim
Young Ah Kim
JSJeong Hwan Shin
Jeong Hwan Shin
Park DC, et al. Ann Lab Med. 2019 Nov;39(6):537-544. https://doi.org/10.3343/alm.2019.39.6.537

1 November 2010 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
GCGo Eun Choi
Go Eun Choi
SLSun Min Lee
Sun Min Lee
JYJongyoun Yi
Jongyoun Yi
SHSANG-HYUN HWANG
SANG-HYUN HWANG
HKHyung Hoi Kim
Hyung Hoi Kim
CCChulhun L. Chang
Chulhun L. Chang
We evaluated high-resolution melting (HRM) curve analysis as a tool for detecting rifampin (RIF) and isoniazid (INH) resistance in Mycobacterium tuberculosis in an accurate, affordable, and rapid manner. Two hundred seventeen M. tuberculosis clinical isolates of known resistance phenotype were used. Twenty-nine known rpoB mutant DNAs, including rare mutations, were also included. Four pairs of primers were designed: rpoB -F/R (for codons 516 to 539 of rpoB ), rpoB -516F/R (for codons 508 to 536 of rpoB ), katG -F/R (for the codon 315 region of katG ), and inhA -F/R (for the nucleotide substitution of C to T at position −15 of inhA ). An HRM curve was generated for each isolate after real-time PCR differentiated the mutant from the wild-type strains. DNA sequencing of the target regions was performed to confirm the results of the HRM curve analysis. All but one of the 73 RIF-resistant (RIF-R) strains and all 124 RIF-susceptible (RIF-S) isolates were correctly identified by HRM curve analysis of rpoB . Twenty-seven of 29 known rpoB mutants were detected. In HRM curve analysis of katG and inhA , 90 INH-R strains that harbored katG or inhA mutations, or both, and all INH-S strains were correctly identified. Ten phenotypically INH-R strains not harboring katG or inhA mutations were not detected. The HRM curve analysis will be a useful method for detection of RIF and INH resistance in M. tuberculosis in a rapid, accurate, simple, and cost-effective manner.

1 December 2021 in Biosensors and Bioelectronics
Verified
Journal Article
Open access
JLJong-Min Lee
Jong-Min Lee
ECEun Jeong Choi
Eun Jeong Choi
JCJae Heun Chung
Jae Heun Chung
KLKi-Wook Lee
Ki-Wook Lee
YLYujin Lee
Yujin Lee
JOJin-Woo Oh
Jin-Woo Oh
There is a growing interest in electronic nose-based diagnostic systems that are fast and portable. However, existing technologies are suitable only for operation in the laboratory, making them difficult to apply in a rapid, non-face-to-face, and field-suitable manner. Here, we demonstrate a DNA-derived phage nose (D2pNose) as a portable respiratory disease diagnosis system requiring no pretreatment. D2pNose was produced based on phage colour films implanted with DNA sequences from mammalian olfactory receptor cells, and as a result, it possesses the comprehensive reactivity of these cells. The manipulated surface chemistry of the genetically engineered phages was verified through a correlation analysis between the calculated and the experimentally measured reactivity. Breaths from 31 healthy subjects and 31 lung cancer patients were collected and exposed to D2pNose without pretreatment. With the help of deep learning and neural pattern separation, D2pNose has achieved a diagnostic success rate of over 75% and a classification success rate of over 86% for lung cancer based on raw human breath. Based on these results, D2pNose can be expected to be directly applicable to other respiratory diseases.